Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Leucht

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Der Urologe. Ausg. A|October 28, 2021
[Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]K Leucht, S Foller, Marc-Oliver Grimm
Der Urologe. Ausg. A|February 2, 2020
[Risk-adapted therapy for metastatic renal cell carcinoma]M-O Grimm, K Leucht, S Foller, et al.
Clinical and Experimental Immunology|May 15, 2013
Impaired removal of Vβ8(+) lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim)K Leucht, M Caj, M Fried, et al.
Laboratory Animals|July 6, 2013
Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory miceP Jirkof, K Leucht, N Cesarovic, et al.
ESMO Open|August 29, 2025
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCCA Fritzsch, K Leucht, N Röber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Der Urologe. Ausg. A|October 28, 2021
[Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]K Leucht, S Foller, Marc-Oliver Grimm
Der Urologe. Ausg. A|February 2, 2020
[Risk-adapted therapy for metastatic renal cell carcinoma]M-O Grimm, K Leucht, S Foller, et al.
Clinical and Experimental Immunology|May 15, 2013
Impaired removal of Vβ8(+) lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim)K Leucht, M Caj, M Fried, et al.
Laboratory Animals|July 6, 2013
Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory miceP Jirkof, K Leucht, N Cesarovic, et al.
ESMO Open|August 29, 2025
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCCA Fritzsch, K Leucht, N Röber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Pageof 1